Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- AbbVie’s Venetoclax Up for Review on Aug. 23; Tecentriq’s Breast Cancer Use, 2nd Biosimilars Also on Agenda
August 16, 2019
- Japan OKs Zetia Generic, Possibly AG, towards December Listing; No Entry for Lyrica This Time
August 16, 2019
- MHLW to Announce New Drug Prices on Aug. 19
August 9, 2019
- MHLW Gives Update on Heptavax, Seeks Cooperation in Stable Hep B Vaccine Supplies
August 8, 2019
- MHLW Compliance Chief Stresses Priorities on PMD Law Amendment, Steady Implementation of Detailing Guidelines
August 8, 2019
- MHLW Begins Discussions on Clinical Use of Human-Embryo Gene Editing
August 5, 2019
- MHLW Pharma Bureau Chief Keen on Early Enactment of PMD Amendment Bill
August 5, 2019
- Tecentriq’s SCLC Use Gets MHLW Panel Nod for September Approval
August 5, 2019
- Cost-Effectiveness Challenge Remains in Adding Rotavirus Vaccine to Public Vaccination Programs: MHLW Panel
August 5, 2019
- Nobelpharma’s Tympanic Membrane Perforation Drug Clears MHLW Panel, September OK Likely
August 2, 2019
- MHLW Finalizing Timing to Announce Post-Oct. 1 NHI Prices, Bureau Chief Hints at August Possibility
August 2, 2019
- Japan OKs FY2020 Budget Guidelines, Sets 530 Billion Yen Request Ceiling for Social Security Cost Rise
August 1, 2019
- Indonesia to Shorten Review Period for Japan-Approved Drugs
July 29, 2019
- Chuikyo to Revisit Generic Price-Band Rule
July 26, 2019
- Apply Essential Drug Price Maintenance Rule Soon after Unprofitability Re-Pricing: FPMAJ
July 25, 2019
- Chuikyo Wraps Up 1st Round of Discussions on 2020 Medical Fee Revision
July 25, 2019
- Chuikyo Cautious about Considering Societal Values in New Drug Pricing
July 25, 2019
- Don’t Cause Confusion in Drug Distribution in Tax-Linked Drug Re-Pricing: JPWA
July 25, 2019
- Industry’s Plea to Scrap PMP Company Criteria Gets Cold Shoulder at Chuikyo
July 25, 2019
- Regenerative Medicine Forum Opposes Lower Premium Rates for Cell & Gene Therapies, Wins Chuikyo Support for New Pricing Scheme
July 24, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…